[In patients hospitalized for COVID-19, does baricitinib reduce 28-days mortality compared to standard treatment, and is it safe?]

Lanthier, L; Plourde, M-É; Cauchon, M

[In patients hospitalized for COVID-19, does baricitinib reduce 28-days mortality compared to standard treatment, and is it safe?] / Chez les sujets hospitalisés pour COVID-19, est-ce que le baricitinib diminue la mortalité à 28jours comparativement aux traitements standards tout en étant sécuritaire ?

Lanthier, L; Plourde, M-É; Cauchon, M.

Lanthier L; Département de médecine spécialisé, service de médecine interne générale, université de Sherbrooke, 580, Bowen Sud, Sherbrooke J1G 2E8, Québec, Canada. Electronic address: lanthier01@videotron.ca.
Plourde MÉ; Département de médecine nucléaire et radiobiologie, service de radio-oncologie, université de Sherbrooke, Sherbrooke, Québec, Canada.
Cauchon M; Département de médecine familiale et de médecine d'urgence, université Laval, Québec, Canada.

Rev Med Interne ; 43(10): 634-635, 2022 10.

Article in French | MEDLINE | ID: covidwho-2036476

Subject(s)

Azetidines; COVID-19; Azetidines/therapeutic use; COVID-19/drug therapy; Humans; Purines/therapeutic use; Pyrazoles; Sulfonamides

Keywords

Baricitinib; COVID-19; Traitement; Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Limits: Humans Language: French Journal: Rev Med Interne Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google